Co-Authors
This is a "connection" page, showing publications co-authored by Celia Cardozo and Pedro Puerta-Alcalde.
Connection Strength
0.532
-
Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019. Clin Infect Dis. 2022 01 07; 74(1):127-132.
Score: 0.062
-
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. J Antimicrob Chemother. 2021 11 12; 76(12):3296-3302.
Score: 0.061
-
Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. BMJ Open. 2021 08 17; 11(8):e040775.
Score: 0.060
-
Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. Infect Dis Ther. 2021 Sep; 10(3):1407-1418.
Score: 0.059
-
Experience with the use of siltuximab in patients with SARS-CoV-2 infection. Rev Esp Quimioter. 2021 Aug; 34(4):337-341.
Score: 0.059
-
Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. Rev Esp Quimioter. 2021 Jun; 34(3):238-244.
Score: 0.059
-
Real-life use of remdesivir in hospitalized patients with COVID-19. Rev Esp Quimioter. 2021 Apr; 34(2):136-140.
Score: 0.058
-
Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. Lancet Reg Health Eur. 2021 Apr; 3:100041.
Score: 0.058
-
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021 Jan; 27(1):83-88.
Score: 0.056